Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 1/20 | 0.68 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.68 |
| ▸ | HDAC1 | Q13547 | 8/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 6/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.55 |
| ▸ | F10 | P00742 | 1/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.52 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.52 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10874930 | 0.88 | MEN1 (0.58) | CACNA1BAPBA1HDAC1ALDH1A1L3MBTL1 | |
| SCHEMBL12506291 | 0.87 | CACNA1B (0.73) | CACNA1BAPBA1HDAC1ALDH1A1L3MBTL1 | |
| SCHEMBL14299600 | 0.86 | CACNA1B (0.66) | CACNA1BAPBA1HDAC1ALDH1A1L3MBTL1 | |
| SCHEMBL14701415 | 0.84 | HPGD (0.70) | CACNA1BAPBA1HDAC1ALDH1A1L3MBTL1 | |
| SCHEMBL27645638 | 0.83 | POLB (0.67) | HDAC1MEN1KMT2AF10HDAC3 | |
| Tacedinaline SCHEMBL144794 | 0.83 | HDAC1 (0.74) | CACNA1BAPBA1HDAC1HDAC3HDAC2 | |
| Tacedinaline SCHEMBL29482198 | 0.83 | HDAC1 (0.74) | CACNA1BAPBA1HDAC1HDAC3HDAC2 | |
| SCHEMBL2989065 | 0.82 | CACNA1B (0.60) | CACNA1BAPBA1HDAC1ALDH1A1L3MBTL1 | |
| SCHEMBL338564 | 0.81 | MEN1 (0.58) | HDAC1ALDH1A1L3MBTL1MEN1KMT2A | |
| SCHEMBL12772616 | 0.81 | NPC1 (0.68) | ALDH1A1L3MBTL1MEN1KMT2AF10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9795597-B2 | Cyclopropylamines as LSD1 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-10-24 | — | — | US | disclosed |
| US-20170239274-A1 | COMBINATION | NOVARTIS PHARMA AG (CH) | 2017-08-24 | — | — | US | disclosed |
| US-20170189408-A1 | NOVEL PHARMACEUTICAL COMPOSITION | NOVARTIS AG (CH) | 2017-07-06 | — | — | US | disclosed |
| US-20170020878-A1 | COMBINATION COMPRISING A BTK INHIBITOR AND AN AKT INHIBITOR | NOVARTIS AG (CH) | 2017-01-26 | — | — | US | disclosed |
| US-20160235714-A1 | ENZALUTAMIDE IN COMBINATION WITH AFURESERTIB FOR THE TREATMENT OF CANCER | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-08-18 | — | — | US | disclosed |
| US-20160228456-A1 | COMBINATION | NOVARTIS PHARMA AG (CH) | 2016-08-11 | — | — | US | disclosed |
| US-20160220547-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-08-04 | — | — | US | disclosed |
| US-9399021-B2 | Pharmaceutical composition | NOVARTIS AG (CH) | 2016-07-26 | — | — | US | disclosed |
| US-9271941-B2 | Pharmaceutical composition | NOVARTIS AG (CH) | 2016-03-01 | — | — | US | disclosed |
| US-20150374859-A1 | Imaging compounds for tracking histone deacetylase inhibitor and synthesis method thereof | INSTITUTE OF NUCLEAR ENERGY RESEARCH (TW) | 2015-12-31 | — | — | US | disclosed |
| US-20150284360-A1 | AMIDE DERIVATIVES OF ANILINE-RELATED COMPOUNDS AND COMPOSITIONS THEREOF | C & C BIOPHARMA LLC (US) | 2015-10-08 | — | — | US | disclosed |
| US-20150284360-A1 | AMIDE DERIVATIVES OF ANILINE-RELATED COMPOUNDS AND COMPOSITIONS THEREOF | C & C BIOPHARMA LLC (US) | 2015-10-08 | — | — | US | disclosed |
| US-9085622-B2 | Antigen binding proteins | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-07-21 | — | — | US | disclosed |
| US-8853408-B2 | Cyclopropylamines as LSD1 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2014-10-07 | — | — | US | disclosed |
| US-20140154316-A1 | NOVEL PHARMACEUTICAL COMPOSITION | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2014-06-05 | — | — | US | disclosed |
| US-20140037726-A1 | NOVEL PHARMACEUTICAL COMPOSITION | GLAXOSMITHKLINE LLC (US) | 2014-02-06 | — | — | US | disclosed |
| US-20140018393-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | Glaxo Smith Kline LLC | 2014-01-16 | — | — | US | disclosed |
| US-20130156779-A1 | NOVEL ANTIGEN BINDING PROTEINS | GLAXO GROUP LIMITED (GB) | 2013-06-20 | — | — | US | disclosed |
| US-20120302579-A1 | CANCER TREATMENT METHOD | GLAXOSMITHKLINE LLC | 2012-11-29 | — | — | US | disclosed |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170239274-A1 | COMBINATION | CYP17A1, HSD17B11, HSD17B1 | CACNA1B 4565/4885APBA1 3263/4885HDAC1 128/4885 |
| US-20160220547-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM3B | CACNA1B 2936/4885APBA1 2786/4885HDAC1 67/4885 |
| US-20150374859-A1 | Imaging compounds for tracking histone deacetylase inhibitor and synthesis method thereof | HDAC7, HDAC8, HDAC1 | CACNA1B 2376/4885APBA1 2805/4885HDAC1 3/4885 |
| US-20120302579-A1 | CANCER TREATMENT METHOD | MPL, TPO, PROKR1 | CACNA1B 4238/4885APBA1 4431/4885HDAC1 4523/4885 |
| US-20130156779-A1 | NOVEL ANTIGEN BINDING PROTEINS | CD2BP2, HSPBP1, LGALS3BP | CACNA1B 4189/4885APBA1 111/4885HDAC1 3555/4885 |
| US-20150284360-A1 | AMIDE DERIVATIVES OF ANILINE-RELATED COMPOUNDS AND COMPOSITIONS THEREOF | AADAC, AAAS, NAT1 | CACNA1B 3410/4885APBA1 883/4885HDAC1 266/4885 |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | BRCA1, IRS1, IGF1R | CACNA1B 3694/4885APBA1 415/4885HDAC1 2055/4885 |
| US-20170020878-A1 | COMBINATION COMPRISING A BTK INHIBITOR AND AN AKT INHIBITOR | BTK, PIK3CD, PIK3CA | CACNA1B 2525/4885APBA1 4084/4885HDAC1 842/4885 |
| US-20140154316-A1 | NOVEL PHARMACEUTICAL COMPOSITION | PHOSPHO1, PLA2G2C, TTR | CACNA1B 3086/4885APBA1 4166/4885HDAC1 1261/4885 |
| US-20140018393-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM3B | CACNA1B 2936/4885APBA1 2786/4885HDAC1 67/4885 |
| US-20160228456-A1 | COMBINATION | CYP17A1, HSD17B11, HSD17B1 | CACNA1B 4600/4885APBA1 3103/4885HDAC1 143/4885 |
| US-20160235714-A1 | ENZALUTAMIDE IN COMBINATION WITH AFURESERTIB FOR THE TREATMENT OF CANCER | AR, PIK3CA, NR5A1 | CACNA1B 1087/4885APBA1 2305/4885HDAC1 7/4885 |
| US-20140037726-A1 | NOVEL PHARMACEUTICAL COMPOSITION | PHOSPHO1, PLA2G2C, TTR | CACNA1B 3086/4885APBA1 4166/4885HDAC1 1261/4885 |
| US-20170189408-A1 | NOVEL PHARMACEUTICAL COMPOSITION | TTR, PHOSPHO1, PLA2G2C | CACNA1B 2730/4885APBA1 4193/4885HDAC1 1427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.